Semin Liver Dis 2000; 20(2): 201-210
DOI: 10.1055/s-2000-9942
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hepatitis C After Liver Transplantation

Patricia A. Sheiner
  • Department of Surgery, The Mount Sinai School of Medicine, Chief, Adult Liver Transplantation Surgery, The Recanati/Miller Transplantation Institute, New York, New York
Further Information

Publication History

Publication Date:
31 December 2000 (online)

ABSTRACT

Hepatitis C is the most common cause of end-stage liver disease leading to liver transplant. The disease can recur after transplant, resulting in clinical hepatitis in up to 75% of patients and severe disease in approximately 7%. Treatment of rejection with steroid boluses and treatment of steroid-resistant rejection with OKT3 have both been shown to increase the incidence of recurrent hepatitis C. The use of OKT3 for steroid-resistant rejection is reportedly associated with more severe recurrence. The calcineurin inhibitors tacrolimus and cyclosporine have not been conclusively associated with different rates or severity of recurrence. Viral levels rise 10- to 15-fold after transplant and appear to be associated with the use of immunosuppression. Studies suggest that high viral levels, either pretransplant or early after transplant, may be associated with severe recurrent disease. Although the role of genotype is still unclear, genotype 1b is known to be associated with a poorer prognosis in nontransplanted patients and a lesser response to treatment than other genotypes. Furthermore, some reports suggest that after transplant, recurrent disease may progress more rapidly in patients with genotype 1. Treatment options after recurrence remain poor. Neither interferon nor ribavirin alone provides any true benefit. Combination therapy appears to have a better short-term outcome but may be poorly tolerated, and long-term benefits are unknown. Prophylaxis with combination therapy may be a better option but requires further study. Finally, retransplantation for recurrent hepatitis C is complicated not by rapid recurrence of disease in the new allograft but by high perioperative mortality that may be predicted by the presence of renal failure or sepsis preretransplant.

REFERENCES

  • 1 Seaberg E, Belle H, Beringer K, Shivins J, Detre K. Liver transplantation in the US from 1987-1998; Updated results from the Pitt-UNOS Liver Transplant Registry. In: Cecka J, Terasaki P, eds. Clinical Transplants 1998 Los Angeles: UCLA Tissue Typing Laboratory 1999
  • 2 Wright T L, Donegan E, Hsu H H. Recurrent and acquired hepatitis C viral infection in liver transplant recipients.  Gastroenterology . 1992;  103 317-322
  • 3 Feray C, Gigou M, Samuel D. The course of hepatitis C virus infection after liver transplantation.  Hepatology . 1994;  20 1137-1143
  • 4 Johnson M W, Washburn K, Freeman R B, FitzMaurice S E, Dienstag J, Basgoz N, Jenkins R L, Cosimi B. Hepatitis C viral infection in liver transplantation.  Arch Surg . 1996;  131 284-291
  • 5 Gane E J, Portmann B C, Naoumov N V, Smith H M, Underhill J A, Donaldson P T, Maertens G, Williams R. Long term outcome of hepatitis C infection after liver transplantation.  N Engl J Med . 1996;  334 815-819
  • 6 Martin P, Munoz S J, Di Bisceglie M A, Rubin R, Waggoner J G, Armenti V T, Moritz M J, Jarrell B E, Maddrey W C. Recurrence of hepatitis C virus infection after orthotopic liver transplantation.  Hepatology . 1991;  13 719-721
  • 7 Wright T L, Donegan E, Hsu H H. Recurrent and acquired hepatitis C viral infection in liver transplant recipients.  Gastroenterology . 1992;  103 317-322
  • 8 Chazouilleres O, Kim M, Combs C. Quantitation of hepatitis C virus RNA in liver transplant recipients.Gastroenterology .  1994;  106 994-999
  • 9 Greenson J K, Svoboda-Newman S M, Merion R M, Frank T S. Histologic progression of recurrent hepatitis C in liver transplant allografts.  Am J Surg Pathol . 1996;  20 731-738
  • 10 Schluger L K, Sheiner P A, Thung S N. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.  Hepatology . 1996;  23 971-976
  • 11 Shah G, Dmetris J, Gavaler J, Lewis J, Todo S, Starzl T, Van Thiel D. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation.  Gastoenterology . 1993;  103 323-329
  • 12 DiBisceglie A M, Goodman Z D, Ishak K G, Hoofnagle J H, Melpolder J J, Alter H J. Long term clinical and histopathological follow-up of chronic posttransfusion hepatitis.  Hepatology . 1991;  14 969-974
  • 13 Sheiner P A, Schwartz M, Mor E. Severe or multiple rejection episodes lead to increased early recurrence of hepatitis C after orthotopic liver transplantation.  Hepatology . 1995;  21 30-34
  • 14 Harrison R F, Davies M H, Goldin R D, Hubscher S G. Recurrent hepatitis B in liver allografts: A distinctive form of rapidly developing cirrhosis.  Histopathology . 1993;  23 21-28
  • 15 Angus P W, Locarnini S A, McCaughan G W, Jones R M, McMillan J S, Bowden D S. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation.  Hepatology . 1995;  21 14-18
  • 16 Dickson R C, Caldwell S H, Ishitani M B, Lau J Y, Driscoll C J, Stevenson W C, McCullough C S, Pruett T L. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation.  Transplantation . 1996;  61 701-705
  • 17 Schoeman M N, Liddle C, Bilous M, Groerson J, Craig P I, Batey R G, Farrell G C. Chronic nonA-nonB hepatitis: Lack of correlation between biochemical and morphological activity and effects of immunosuppressive therapy on disease progression.  Aust NZ J Med . 1990;  20 56-62
  • 18 Fong T L, Valinluck B, Govindarajan S, Charboneau F, Adkins R H, Redeker A G. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C.  Gastroenterology . 1994;  107 196-199
  • 19 Magrin S, Craxi A, Fabiano C. Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid treatment.  Hepatology . 1994;  19 273-279
  • 20 Bonacini M, Govindarajan S, Blatt L M, Schmid P, Conrad A, Lindsay K L. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA.  J Virol Hepatol . 1999;  6 203-208
  • 21 Rosen H R, Shackleton C R, Higa L. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.  Am J Gastroenterol . 1997;  92 1453-1457
  • 22 Prieto M, Berenguer M, Rayon J M. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes.  Hepatology . 1999;  29 250-256
  • 23 Berenguer M, Prieto M, Cordoba J. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection.  J Hepatol . 1998;  28 756-763
  • 24 Charlton M, Seaberg E, for the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Impact of immunosuppression and acute rejection of recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.  Liver Transplant Surg . 1999;  5 S107-S114
  • 25 O'Grady J G, Sutherland S, Harvey F. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in the pathogenesis of vanishing bile duct syndrome after liver transplantation.  Lancet . 1988;  2 302
  • 26 Pouteil-Noble C, Ecochard R, Landrivon G. Cytomegalovirus infection-an etiological factor for rejection?.  Transplantation . 1993;  55 851-857
  • 27 Farges O, Saliba F, Hosseine F. Incidence of rejection and infection after liver transplantation as a function of the primary disease: Possible influence of alcohol and polyclonal immunoglobulins.  Hepatology . 1996;  23 240-248
  • 28 Singh N, Gayowski T, Ndimbie O K, Nedjar S, Wagener M M, Yu V L. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation.  Surgery . 1996;  119 452-456
  • 29 Loinaz C, Lumbreras C, Gonzalez-Pinto I. High incidence of posttransplant hepatitis and chronic rejection associated with hepatitis C virus infection in liver transplant recipients.  Transplant Proc . 1995;  27 1217-1218
  • 30 Hoffmann R M, Gunther C, Diepolder H M, Zachoval R, Eissner H J, Forst H, Anthuber M, Paumgartner G, Pape G R. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation.  Transplant Int . 1995;  8 353-359
  • 31 Kakumu S, Takayanagi M, Iwata K, Okumura A, Aiyama T, Ishikawa T, Nadai M, Yoshioka K. Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C.  J Gastroenterol Hepatol . 1997;  12 62-66
  • 32 Sheiner P A, Boros P, Klion F M. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.  Hepatology . 1998;  28 831-838
  • 33 Flamm S L, Marcos A, Jenkins R L. Tacrolimus is associated with decreased survival in patients undergoing liver transplantation with chronic hepatitis C infection. Presented at the 15th annual meeting of the American Society of Transplant Physicians , Dallas, Texas, May 1996
  • 34 Casavilla A, Mateo R, Rakela J. Impact of hepatitis C viral infection on survival following primary liver transplantation under FK 506 (Prograf) [Abstract]. AASLD Single Topic Symposium, Reston, Virginia, March 1995
  • 35 Casavilla F A, Rakela J, Kapur S. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus.  Liver Transplant Surg . 1998;  4 448-454
  • 36 Lake J R, for the US FK506 Multicenter Trial Investigators. Outcome of hepatitis C virus-infected primary liver transplants: 5 year follow up of the US randomized comparartive study. Abstract presented at the 16th annual meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 1997
  • 37 Zervos X A, Weppler D, Fagulidis G P. Comparison of tacrolimus with micro-emulsion CyA as primary immunosuppression in hepatitis C patients after liver transplantation.  Transplantation . 1998;  65 1044-1046
  • 38 Ghobrial R M, Farmer D G, Baquerizo A. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.  Ann Surg . 1999;  229 824-831
  • 39 Neyts J, Meerbach A, McKenna P, De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.  Antiviral Res . 1996;  30 125-132
  • 40 Platz K P, Mueller A R, Berg T, Neuhaus R, Hopf U, Lobeck H, Neuhaus P. Searching for the optimal management of hepatitis C patients after liver transplantation.  Transplant Int . 1998;  11(Suppl 1) S209-S211
  • 41 Paterson D L, Singh N, Panebianco A, Wannstedt C F, Wagener M M, Gayowski T, Marino I R. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil.  Transplantation . 1998;  66 593-598
  • 42 Chazouilleres O, Kim M, Ferrell L. Quantitative study of hepatitis C virus in liver transplant recipients.  Gastroenterology . 1994;  106 994-999
  • 43 Freeman R, Tran S, Lee Y M. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis.  Transplantation . 1996;  61 542-545
  • 44 Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J. Predictors of patient and graft survival following liver transplantation for hepatitis C.  Hepatology . 1998;  28 823-830
  • 45 Doughty A L, Spencer J D, Cossart Y E, McCaughan G W. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels.  Liver Transplant Surg . 1998;  4 15-21
  • 46 Gane E J, Naoumov N V, Qian K P. Longitudinal analysis of hepatitis C virus replication following liver transplantation.  Gastroenterology . 1996;  110 167-177
  • 47 Berg T, Hopf U, Bechstein W O, Muller A R, Fukumoto T, Neuhaus R, Lobeck H, Neuhaus P. Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation.  Transplantation . 1998;  66 225-228
  • 48 Moll C, Kahler C, Edis C, Nachbauer K, Konigsrainer A, Spechtenhauser B, Margreiter R, Vogel W. Early-level hepatitis C viremia after orthotopic liver transplantation is of prognostic significance.  Transplant Proc . 1998;  30 698-700
  • 49 Almasio P L, Di Marco V, Bonura C. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.  Dig Dis Sci . 1999;  44 1013-1019
  • 50 Bellentani S, Pozzato G, Saccoccio G. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study.  Gut . 1999;  44 874-880
  • 51 Vandelli C, Renzo F, Braun H B. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C.  J Med Virol . 1999;  58 26-34
  • 52 Feray C, Gigou M, Samuel D. Influence of the genotype of hepatitis C virus on the severity of recurrent liver disease after liver transplantation.  Gastroenterology . 1995;  108 1314-1317
  • 53 Gordon F D, Poterucha J J, Germer J, Zein N N, Batts K P, Gross Jr B J, Wiesner R, Persing D. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation.  Transplantation . 1997;  63 1419-1423
  • 54 Pageaux G P, Ducos J, Mondain A M, Costes B, Picot M C, Perrigault P F, Domergue J, Larrey D, Michel H. Hepatitis C virus genotypes and quantitation of serum hepatits C virus RNA in liver transplant recipients: Relationsip with severity of histological recurrence and implications in the pathogenesis of HCV infection.  Liver Transplant Surg . 1997;  3 501-505
  • 55 Sheiner P A, Kim-Schluger L, Emre S. Retransplantation for recurrent hepatitis C.  Liver Transplant Surg . 1997;  3 130-136
  • 56 Zhou S, Terrault N A, Ferrell L. Severity of liver diseas in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia.  Hepatology . 1996;  24 1041-1046
  • 57 Vargas H E, Laskus T, Wang L F. The influence of hepatitis C virus genotype on the outcome of liver transplantation.  Liver Transplant Surg . 1998;  4 22-27
  • 58 Wright H I, Gavaler J S, Van Theil H D. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients.  Transplantation . 1992;  53 121-124
  • 59 Wright T L, Combs C, Kim M. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.  Hepatology . 1994;  20(4 Pt 1) 773-779.
  • 60 Lau J Y, Davis G l, Kniffen J, Qian K P, Urdea M S, Chan C S, Mizokami M, Neuwald P D, Wilber J C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.  Lancet . 1993;  341 1501-1504
  • 61 Yamada G, Takatani M, Kishi F. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.  Hepatology . 1995;  22 1351-1354
  • 62 Feray C, Samuel D, Gigou M, Paradis V, David M F, Lemonnier C, Reynes M, Bismuth H. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection.  Hepatology . 1995;  22(4 Pt 1) 1084-1089
  • 63 Jain A, Demetris A J, Manez R, Tsamanadas A C, Van Thiel D, Rakela J, Starzl T E, Fung J J. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon.  Liver Transplant Surg . 1998;  4 197-203
  • 64 Cattral M S, Hemming A W, Wanless I R, Al Ashgar H, Krajden M, Lilly L, Greig P D, Levy G A. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.  Transplantation . 1999;  67 1277-1280
  • 65 Gane E J, Lo S K, Riordan S M, Portmann B C, Lau J Y, Naoumov N V, Williams R. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation.  Hepatology . 1998;  27 1403-1407
  • 66 Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, Trepo C. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.  Hepatology . 1997;  26 500-504
  • 67 Singh N, Gayowski T, Wannstedt C F, Shakil A O, Wagener M M, Fung J J, Marino I R. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial.  Transplantation . 1998;  65 82-86
  • 68 Mazzaferro V, Regalia E, Pulvirenti A. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination.  Transplant Proc . 1997;  29 519-521
  • 69 Rosen H R, O'Reilly P M, Shackleton C R. Graft loss following liver transplantation in patients with chronic hepatitis C.  Transplantation . 1996;  62 1773-1776
  • 70 Feray C, Habasanne A, Samuel D, Farges O, Reynes M, Bismuth H. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus.  Hepatology . 1995;  22 135A
  • 71 Facciuto M, Heidt D, Guarrera J. Retransplantation for late liver graft failure: Predictors of mortality.  Liver Transplant . 2000;  6 174-179
  • 72 Singh N, Gayowski T, Wagener M M, Marino I R. Increased infections in liver transplant recipients with recurrent hepatitis C virus (HCV) hepatitis.  Transplantation . 1996;  61 402-406
    >